title: Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia.
authors.forename: Ayalew
authors.initials: A
authors.lastname: Tefferi
authors.forename: Ralph
authors.initials: R
authors.lastname: Levitt
authors.forename: Terra L
authors.initials: TL
authors.lastname: Lasho
authors.forename: Ryan A
authors.initials: RA
authors.lastname: Knudson
authors.forename: Rhett P
authors.initials: RP
authors.lastname: Ketterling
mesh_terms: D000368:Aged; D019943:Amino Acid Substitution; D000970:Antineoplastic Agents / Q000009:adverse effects; D001549:Benzamides; D016313:Genes, abl; D006801:Humans; D000068877:Imatinib Mesylate; D053614:Janus Kinase 2 / Q000235:genetics*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D008297:Male; D020125:Mutation, Missense; D010879:Piperazines / Q000009:adverse effects*; D011087:Polycythemia Vera / Q000201:enzymology / Q000209:etiology* / Q000235:genetics; D011743:Pyrimidines / Q000009:adverse effects*; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C507924:JAK2 protein, human; D053614:Janus Kinase 2